Disease-Free Survival

Pediatric-style chemotherapy produced superior disease-free survival compared to myeloablative allogeneic HCT in AYAs with Ph-negative ALL in CR1.

Effect: improvement; HR 1.62 (HCT vs chemotherapy); CI: 95% CI 1.25–2.12

Pediatric-style chemotherapy produced superior disease-free survival compared to myeloablative allogeneic HCT in AYAs with Ph-negative ALL in CR1.

Effect: improvement; HR 1.62 (HCT vs chemotherapy); CI: 95% CI 1.25–2.12

Pediatric-style chemotherapy produced superior disease-free survival compared to myeloablative allogeneic HCT in AYAs with Ph-negative ALL in CR1.

Effect: improvement; HR 1.62 (HCT vs chemotherapy); CI: 95% CI 1.25–2.12

Pediatric-style chemotherapy produced superior disease-free survival compared to myeloablative allogeneic HCT in AYAs with Ph-negative ALL in CR1.

Effect: improvement; HR 1.62 (HCT vs chemotherapy); CI: 95% CI 1.25–2.12

Pediatric-style chemotherapy produced superior disease-free survival compared to myeloablative allogeneic HCT in AYAs with Ph-negative ALL in CR1.

Effect: improvement; HR 1.62 (HCT vs chemotherapy); CI: 95% CI 1.25–2.12

Pediatric-style chemotherapy produced superior disease-free survival compared to myeloablative allogeneic HCT in AYAs with Ph-negative ALL in CR1.

Effect: improvement; HR 1.62 (HCT vs chemotherapy); CI: 95% CI 1.25–2.12

Pediatric-style chemotherapy produced superior disease-free survival compared to myeloablative allogeneic HCT in AYAs with Ph-negative ALL in CR1.

Effect: improvement; HR 1.62 (HCT vs chemotherapy); CI: 95% CI 1.25–2.12

Pediatric-style chemotherapy produced superior disease-free survival compared to myeloablative allogeneic HCT in AYAs with Ph-negative ALL in CR1.

Effect: improvement; HR 1.62 (HCT vs chemotherapy); CI: 95% CI 1.25–2.12

Pediatric-style chemotherapy produced superior disease-free survival compared to myeloablative allogeneic HCT in AYAs with Ph-negative ALL in CR1.

Effect: improvement; HR 1.62 (HCT vs chemotherapy); CI: 95% CI 1.25–2.12

Pediatric-style chemotherapy produced superior disease-free survival compared to myeloablative allogeneic HCT in AYAs with Ph-negative ALL in CR1.

Effect: improvement; HR 1.62 (HCT vs chemotherapy); CI: 95% CI 1.25–2.12

Pediatric-style chemotherapy produced superior disease-free survival compared to myeloablative allogeneic HCT in AYAs with Ph-negative ALL in CR1.

Effect: improvement; HR 1.62 (HCT vs chemotherapy); CI: 95% CI 1.25–2.12

Pediatric-style chemotherapy produced superior disease-free survival compared to myeloablative allogeneic HCT in AYAs with Ph-negative ALL in CR1.

Effect: improvement; HR 1.62 (HCT vs chemotherapy); CI: 95% CI 1.25–2.12

Pediatric-style chemotherapy produced superior disease-free survival compared to myeloablative allogeneic HCT in AYAs with Ph-negative ALL in CR1.

Effect: improvement; HR 1.62 (HCT vs chemotherapy); CI: 95% CI 1.25–2.12

Pediatric-style chemotherapy produced superior disease-free survival compared to myeloablative allogeneic HCT in AYAs with Ph-negative ALL in CR1.

Effect: improvement; HR 1.62 (HCT vs chemotherapy); CI: 95% CI 1.25–2.12

Pediatric-style chemotherapy produced superior disease-free survival compared to myeloablative allogeneic HCT in AYAs with Ph-negative ALL in CR1.

Effect: improvement; HR 1.62 (HCT vs chemotherapy); CI: 95% CI 1.25–2.12

Pediatric-style chemotherapy produced superior disease-free survival compared to myeloablative allogeneic HCT in AYAs with Ph-negative ALL in CR1.

Effect: improvement; HR 1.62 (HCT vs chemotherapy); CI: 95% CI 1.25–2.12

Pediatric-style chemotherapy produced superior disease-free survival compared to myeloablative allogeneic HCT in AYAs with Ph-negative ALL in CR1.

Effect: improvement; HR 1.62 (HCT vs chemotherapy); CI: 95% CI 1.25–2.12

Pediatric-style chemotherapy produced superior disease-free survival compared to myeloablative allogeneic HCT in AYAs with Ph-negative ALL in CR1.

Effect: improvement; HR 1.62 (HCT vs chemotherapy); CI: 95% CI 1.25–2.12

Pediatric-style chemotherapy produced superior disease-free survival compared to myeloablative allogeneic HCT in AYAs with Ph-negative ALL in CR1.

Effect: improvement; HR 1.62 (HCT vs chemotherapy); CI: 95% CI 1.25–2.12

Pediatric-style chemotherapy produced superior disease-free survival compared to myeloablative allogeneic HCT in AYAs with Ph-negative ALL in CR1.

Effect: improvement; HR 1.62 (HCT vs chemotherapy); CI: 95% CI 1.25–2.12

Pediatric-style chemotherapy produced superior disease-free survival compared to myeloablative allogeneic HCT in AYAs with Ph-negative ALL in CR1.

Effect: improvement; HR 1.62 (HCT vs chemotherapy); CI: 95% CI 1.25–2.12

Pediatric-style chemotherapy produced superior disease-free survival compared to myeloablative allogeneic HCT in AYAs with Ph-negative ALL in CR1.

Effect: improvement; HR 1.62 (HCT vs chemotherapy); CI: 95% CI 1.25–2.12

Pediatric-style chemotherapy produced superior disease-free survival compared to myeloablative allogeneic HCT in AYAs with Ph-negative ALL in CR1.

Effect: improvement; HR 1.62 (HCT vs chemotherapy); CI: 95% CI 1.25–2.12

Pediatric-style chemotherapy produced superior disease-free survival compared to myeloablative allogeneic HCT in AYAs with Ph-negative ALL in CR1.

Effect: improvement; HR 1.62 (HCT vs chemotherapy); CI: 95% CI 1.25–2.12

Pediatric-style chemotherapy produced superior disease-free survival compared to myeloablative allogeneic HCT in AYAs with Ph-negative ALL in CR1.

Effect: improvement; HR 1.62 (HCT vs chemotherapy); CI: 95% CI 1.25–2.12

Pediatric-style chemotherapy produced superior disease-free survival compared to myeloablative allogeneic HCT in AYAs with Ph-negative ALL in CR1.

Effect: improvement; HR 1.62 (HCT vs chemotherapy); CI: 95% CI 1.25–2.12

Pediatric-style chemotherapy produced superior disease-free survival compared to myeloablative allogeneic HCT in AYAs with Ph-negative ALL in CR1.

Effect: improvement; HR 1.62 (HCT vs chemotherapy); CI: 95% CI 1.25–2.12